[PDF][PDF] Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists
The genotypic determination of HIV tropism to guide the use of maraviroc, the first CCR5
antagonist with specific antiviral activity against CCR5 (R5)-tropic HIV variants, has been …
antagonist with specific antiviral activity against CCR5 (R5)-tropic HIV variants, has been …
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition
HIV-1 entry begins with viral envelope glycoprotein gp120 interacting with host-cell CD4 and
an entry coreceptor (mainly chemokine receptors CCR5 or CXCR4). Inhibitors of particular …
an entry coreceptor (mainly chemokine receptors CCR5 or CXCR4). Inhibitors of particular …
Effect of maraviroc on HIV disease progression-related biomarkers
MC Romero-Sánchez, K Machmach… - Antimicrobial agents …, 2012 - Am Soc Microbiol
The potential effect of blocking the CCR5 receptor on HIV disease progression biomarkers is
not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test …
not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test …
The role of genetic variants of stromal cell-derived factor 1 in pediatric HIV-1 infection and disease progression
K Gianesin, R Freguja, F Carmona, M Zanchetta… - 2012 - journals.plos.org
Stromal cell-Derived Factor 1 (SDF1) is the natural ligand of CXCR4, the coreceptor of HIV-1
X4 viruses. This study investigated the role of the single nucleotide polymorphism (SNP) …
X4 viruses. This study investigated the role of the single nucleotide polymorphism (SNP) …
Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods
A Gonzalez-Serna, RA McGovern… - Antimicrobial agents …, 2012 - Am Soc Microbiol
Genotypic tropism testing methods are emerging as the first step before prescription of the
CCR5 antagonist maraviroc (MVC) to HIV-infected patients in Europe. Studies validating …
CCR5 antagonist maraviroc (MVC) to HIV-infected patients in Europe. Studies validating …
Reduced baseline sensitivity to maraviroc inhibition among R5 HIV-1 isolates from individuals with severe immunodeficiency
U Karlsson, J Repits, L Antonsson… - JAIDS Journal of …, 2016 - journals.lww.com
antagonist resistance. 15-18, 21, 27, 29-32 However, these mutations have been Env
context-dependent and there are no universal genotypic markers to distinguish resistant R5 …
context-dependent and there are no universal genotypic markers to distinguish resistant R5 …
Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism …
B Rossetti, C Bianco, LI Bellazzi… - AIDS Research and …, 2014 - liebertpub.com
We assessed the immunovirological response to antiretroviral regimens containing
maraviroc in HIV-infected viremic patients with viral tropism predicted by different assays …
maraviroc in HIV-infected viremic patients with viral tropism predicted by different assays …
Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients
M Genebat, RS de Pablo-Bernal, I Pulido… - Antiviral Research, 2015 - Elsevier
Our aim was to analyze the virological response to a combined antiretroviral therapy started
after Maraviroc Clinical Test (MCT) in naïve HIV-infected patients. Forty-one patients were …
after Maraviroc Clinical Test (MCT) in naïve HIV-infected patients. Forty-one patients were …
Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment
M Genebat, I Pulido, MC Romero-Sánchez… - Antiviral research, 2012 - Elsevier
The maraviroc clinical test (MCT) is a clinical approach to establish the indication of
maraviroc treatment. In this study, we analysed the long-term outcome of patients receiving a …
maraviroc treatment. In this study, we analysed the long-term outcome of patients receiving a …
Durability and effectiveness of Maraviroc-containing regimens in HIV-1-infected individuals with virological failure in routine clinical practice
V Potard, J Reynes, T Ferry, C Aubin, L Finkielsztejn… - Plos one, 2015 - journals.plos.org
Introduction Limited data are available on the durability and effectiveness of maraviroc in
routine clinical practice. We assessed the durability of maraviroc-containing regimens during …
routine clinical practice. We assessed the durability of maraviroc-containing regimens during …